BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer

Katherine A. Giles1,2,3, Cathryn M. Gould1, Joanna Achinger-Kawecka1,4, Scott G. Page2, Georgia R. Kafer2, Samuel Rogers2, Phuc-Loi Luu1,4, Anthony J. Cesare2, Susan J. Clark1,4† and Phillippa C. Taberlay3*†

Abstract
Background: BRG1 (encoded by SMARCA4) is a catalytic component of the SWI/SNF chromatin remodelling complex, with key roles in modulating DNA accessibility. Dysregulation of BRG1 is observed, but functionally uncharacterised, in a wide range of malignancies. We have probed the functions of BRG1 on a background of prostate cancer to investigate how BRG1 controls gene expression programmes and cancer cell behaviour.

Results: Our investigation of SMARCA4 revealed that BRG1 is over-expressed in the majority of the 486 tumours from The Cancer Genome Atlas prostate cohort, as well as in a complementary panel of 21 prostate cell lines. Next, we utilised a temporal model of BRG1 depletion to investigate the molecular effects on global transcription programmes. Depleting BRG1 had no impact on alternative splicing and conferred only modest effect on global expression. However, of the transcriptional changes that occurred, most manifested as down-regulated expression. Deeper examination found the common thread linking down-regulated genes was involvement in proliferation, including several known to increase prostate cancer proliferation (KLK2, PCAT1 and VAV3). Interestingly, the promoters of genes driving proliferation were bound by BRG1 as well as the transcription factors, AR and FOXA1. We also noted that BRG1 deple- tion repressed genes involved in cell cycle progression and DNA replication, but intriguingly, these pathways operated independently of AR and FOXA1. In agreement with transcriptional changes, depleting BRG1 conferred G1 arrest.

Conclusions: Our data have revealed that BRG1 promotes cell cycle progression and DNA replication, consistent with the increased cell proliferation associated with oncogenesis.

Keywords: BRG1, SMARCA4, Chromatin remodelling, Cancer, Gene expression, Cell cycle, Transcription, DNA replication

Background
Nucleosomes serve as a physical backbone for chromatin organisation on a global scale and at local gene regulatory elements. Nucleosomes therefore govern both genome-wide stability and local DNA accessibility [1].

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
general transcription machinery [4, 5]. In agreement, ChIP-seq data show that transcription factors are concentrated on accessible DNA, with the highest levels of bound transcription factors correlating with the most accessible genomic regions [6]. Conversely, chromatin condensation resulting in reduced DNA accessibility is necessary for transcriptional repression [7]. Disruption to the DNA accessibility landscape is a feature of cancer [2, 8, 9]. This was recently emphasised in genomic sequencing data from multiple cancers and cancer subtypes, which revealed associations between the accessible chromatin organisation and mutation load [8]. Moreover, studies of aged human and yeast cells demonstrated that nucleosome loss compromises genome stability, gene regulation and transcription [10, 11].

Genes encoding ATP-dependent chromatin remodelers are themselves frequently mutated and often atypically expressed in cancer [5, 12–16]. Notably, the SWI/SNF (switch/sucrose non-fermentable) chromatin remodelling complex is mutated or transcriptionally deregulated in ~20% of cancers; a mutation frequency approaching that of TP53 (~26%) [12, 14, 17]. The SWI/SNF complex is often described as a tumour suppressor because it is required by the Retinoblastoma protein (Rb) family for regulation of normal cell growth [18, 19]. Disruptions of multiple SWI/SNF subunits are reported in human tumours and cell lines [13–15, 20–37], often accompanied by a loss of heterozygosity consistent with the inactivation of a tumour suppressor [13, 34]. The specific SWI/SNF mutations observed in tumours and the cancers associated with altered SWI/SNF function have been extensively reviewed [12–15, 26, 31, 34, 38]. However, the mechanism and functional consequences of SWI/SNF dysregulation are still being defined.

Brahma-related gene 1 (BRG1) is one of the two mutually exclusive ATPases within the SWI/SNF complex. Interestingly, SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, Subfamily A, Member 4), the gene encoding BRG1, has been observed in both down- and up-regulated states in cancer, indicative of the diverse and complex BRG1 functions. SMARCA4 mRNA was seen to be down-regulated in bladder, colon, non-triple negative breast cancers, head and neck, oesophageal, melanoma, pancreatic, lung and ovarian cancers, and SMARCA4 mutation rates in these cancers have been reported between 4 and 13% [12–14, 22, 24, 30, 39–41]. In contrast, SMARCA4 has been reported as over expressed in cancers of the prostate, triple negative breast cancers and some leukemias [12, 22, 24, 30, 42, 43]. In SMARCA4 over expressing cancers, no significant recurrent mutations have been reported [42, 44–46]. The importance of BRG1 in cancer is further evidenced through studies of synthetic lethality, where BRG1 was observed to have a synthetic lethal relationship with the alternative SWI/SNF ATPase Brahma (BRM), and Aurora A kinase in lung cancer, and PTEN in prostate cancer [43, 47, 48].

Examination of multiple prostate cancer cohorts has demonstrated elevated SMARCA4 expression or increased BRG1 protein levels. Clinical studies of primary prostate tumours reported an overall increase in BRG1 protein by immunohistochemistry [42–46], and increased SMARCA4 gene expression has been reported in tumours from The Cancer Genome Atlas (TCGA) prostate cancer cohort compared to normal prostate tissue [49, 50]. Moreover, higher SMARCA4 gene expression or increased BRG1 protein levels are inversely correlated with patient survival [43, 49]. While it is established that BRG1 is commonly up-regulated in prostate cancer, the full range of molecular pathways impacted by dysregulated BRG1 levels and the contribution of these molecular changes to the atypical phenotype of prostate cancer cells remains unclear.

BRG1 has known roles in regulating DNA for temporal gene expression at both promoters and enhancer gene regulatory elements [4, 51–56]. Moreover, BRG1 maintains the epigenetic landscape of a cell at these gene regulatory elements. Specifically, BRG1 has been directly linked to transcriptional output through its recognition of H3K14ac [57–59]. In the absence of H3K14ac, BRG1 is still present at promoters and histones are disassembled from the chromatin; however, transcription is reduced [60]. At enhancers, BRG1 depletion greatly reduces H3K27ac and subtly reduces H3K4me1, which is correlated with a decrease in chromatin accessibility [53]. BRG1 is also known to mediate inter-chromosomal looping interactions between specific loci such as the MYC enhancer and promoter, the alpha-globulin genes, the IgH locus and the class II major histocompatibility complex gene locus [24, 61–64]. On a global scale, BRG1 binding has been found at DNA-loop anchors [56] and topological associated domain (TAD) boundaries where it increases their stability [65]. Together, this demonstrates an important role for BRG1 in maintaining chromatin architecture at both local and global levels for transcription regulation.

Here, we dissected the molecular role of BRG1 on the transcriptome in prostate cancer. We confirmed that SMARCA4 is over-expressed in prostate cancer irrespective of molecular subtype, and identified SMARCA4 was also over expressed in a panel of prostate cancer cell lines. Depletion of BRG1 in LNCaP prostate cancer cells resulted in a modest effect on global gene transcription with most changes resulting in down-regulated gene expression. Within the cohort of down-regulated genes in BRG1 depleted cells, we identified gene clusters...
defined by their co-occupancy or independence from the androgen receptor (AR) and Forkhead box A1 (FOXA1) transcription factors, both of which are known BRG1 co-activators [66–68]. Our data revealed that BRG1, AR and FOXA1 co-regulate known prostate cancer genes KLK2, PCAT1 and VAV3. Gene ontology analysis further revealed that genes regulated by BRG1 independent of AR and FOXA1 include factors regulating cell cycle and proliferation processes including DNA replication. In agreement, depleting BRG1 promoted G1 arrest resulting in reduced cell proliferation. Cumulatively, the data indicate that BRG1 promotes expression of cellular proliferation factors and cancer-associated genes in prostate cancer cells.

Results

SMARCA4 is over expressed in prostate cancer irrespective of molecular subtype

We first examined the expression of SMARCA4 in the TCGA [50] prostate normal and cancer cohort. The 486 tumour samples were subset into the seven TCGA categorised molecular subtypes of prostate cancer [50]. These included those with fusion genes involving ERG (46%), ETV1 (8%), ETV4 (4%) and FLI1 (1%), or those with mutations in SPOP (11%), FOXA1 (3%) or IDH1 (1%) [50]. The remaining samples were grouped as ‘other’ (26%). Each subtype exhibited a statistically significant increase in SMARCA4 expression (p < 0.05) with the exception of the FLI1’ subtype (p = 0.5899) and ‘other’ (p = 0.1899), which both demonstrated a non-significant increase in SMARCA4 expression (Fig. 1a). Previous work examining SMARCA4 expression in the TCGA prostate cancer cohort demonstrated that it is also up-regulated irrespective of Gleason score [49]. Therefore, we conclude that at the mRNA level, SMARCA4 is universally over-expressed in prostate cancer, regardless of clinical grade or molecular subtype.

SMARCA4 is over expressed in prostate cancer and transformed prostate cell lines

We next examined both BRG1 protein and SMARCA4 gene expression levels in normal prostate epithelial cells (PrEC) and compared to LNCaP (lymph node metastasis), an androgen-sensitive prostate cancer cell line, as well as PC3 (bone metastasis), an androgen-insensitive prostate cancer cell line. We found that SMARCA4 gene expression was increased ~ninefold in LNCaP cells and ~sixfold in PC3 compared to PrEC (p < 0.001; Fig. 1b). Further, the BRG1 protein level was increased ~20 and ~24 fold, respectively, in each of the prostate cancer cell lines compared to PrEC (Fig. 1c).

We compared this to published RNA-seq data of several normal, cancer and transformed prostate cell lines [69]. The mean expression of SMARCA4 was significantly increased in both the cancer cell lines and the transformed cell lines compared to the normal cells (p = 0.0148 and p = 0.0353, respectively; Fig. 1d). The exception was DU145 cells that has a known frameshift mutation in SMARCA4, resulting in reduced expression [36]. These data show that common prostate cancer cell lines reflect the same pattern of increased BRG1 protein that is observed in prostate tumours compared to normal prostate samples and therefore provides an appropriate model system to explore the functional consequences of BRG1 dysregulation on the transcriptome.

BRG1 is required for the maintenance of active gene expression

Our previous work has shown that BRG1 occupancy is enriched at active promoter and enhancer gene regulatory elements in LNCaP cells [56]. We therefore hypothesised that BRG1 would play an important role in maintaining the transcriptional profile of these cells. To assess this, we depleted the level of BRG1 protein using two independent siRNAs targeting SMARCA4 (si-SMARCA4-1 and si-SMARCA4-2) and performed RNA-seq at 72 and 144 h post-transfection (Fig. 2a). Our RNA-seq data confirmed successful depletion of the SMARCA4 transcript (~80%) at both time points (Fig. 2b). To confirm a decrease in BRG1 function, we performed a Western blot for BRG1 protein levels. We found BRG1 protein levels reduced to ~50% of the non-targeting control at 72 h, and to ~20% of the non-targeting control at 144 h post-transfection (Fig. 2c, d). We note that there were no significant changes detected in the gene expression of any other SWI/SNF subunit proteins (Additional file 1: Figure 1A). Further quality assessment of the RNA-seq data through a principal component analysis demonstrated that the samples separated by time-point on the first dimension, accounting for 43.39% of the sample variance (Additional file 1: Figure 1B). We performed a differential gene expression analysis and identified 169 down-regulated genes and 24 up-regulated genes (logFC > 1.5, FDR < 0.05) at 72 h post BRG1 depletion (Fig. 2e). This increased to 800 down-regulated genes and 174 up-regulated genes by 144 h post-transfection (Fig. 2f). This suggests that the primary role of BRG1 in LNCaP cells is to maintain active gene expression of a subset of genes.

BRG1 does not function in the regulation of alternative splicing

The nucleosome barrier within genes is reported to contribute to alternative splicing, where there is a higher conservation of nucleosomes at the splice sites of constitutive exons compared to skipped exons [70–72].
Since the contribution of BRG1 to alternative splicing regulation is unknown, we investigated whether this may contribute to the BRG1-dependent changes in gene expression. To do this, we performed a multivariate analysis of transcript splicing (MATS; [73–75]) of our entire RNA-seq datasets. After 72 h of BRG1 depletion, MATS pairwise comparison detected a genome wide total of 13 and 11 skipped exons, and 14 and 9 retained introns with si-SMARCA4-1 and si-SMARCA4-2, respectively (Additional file 1: Figure 1C). At 144 h post BRG1 knockdown, this increased to 240 and 260 skipped exons, and 27 and 26 retained introns with si-SMARCA4-1 and si-SMARCA4-2, respectively (Additional file 1: Figure 1D).

Fig. 1 SMARCA4 (BRG1) is over expressed in prostate cancer. a SMARCA4 gene expression (logPRKM) in TCGA data (tumours n = 486, normal= 52) with tumour samples separated by molecular subtype defined by the TCGA. SMARCA4 expression is increased across all groups, with subtypes ERG, ETV1, ETV4, IDH1, SPOP and FOXA1 all significantly up-regulated, one-way ANOVA Dunnett’s multiple comparison correction **p < 0.05. b SMARCA4 gene expression in prostate cell lines normalised to 18S and relative to PrEC (n = 2). Significance determined by one-way ANOVA with Tukey’s multiple comparison correction ***p < 0.001. Bars denote mean, and error bars are SD. c Representative Western blot of BRG1 protein level in prostate cell lines. Quantification above Western blot by adjusted relative density normalised to GAPDH and relative to PrEC. d Expression of SMARCA4 from RNA-seq in prostate cell lines grouped as normal, cancer or transformed. The mean of each group was calculated, and a significance was tested by one-way ANOVA Dunnett’s multiple comparison correction, **p < 0.05
the MATS analysis identified retention of the first intron from the Kallikrein 3 gene, which encodes prostate specific antigen (PSA) (Additional file 1: Figure 1E). This splice variant has previously been reported in LNCaP cells and generates a unique protein from canonical PSA [76]. While PSA has a well-known link to prostate cancer, the function of its alternative splice variant remains unknown.

**BRG1 binding is associated with expression of prostate cancer associated genes**

We further examined our RNA-seq datasets to determine which genes showed a significant change in expression at 72 h that was maintained at 144 h. Of the genes that were down-regulated at the 72 h time point, 126 genes (75%) remained down-regulated at 144 h. Similarly, of the up-regulated genes, 16 (67%) remained up-regulated at the extended time point (Fig. 2g). Within the down-regulated gene set, we note a number of genes that have previously been associated with increased proliferation in prostate cancer; these include kallikrein 2 (KLK2), long non-coding RNA prostate cancer associated transcript 1 (PCAT1), Vav guanine nucleotide exchange factor 3 (VAV3) [69, 77–84] (Fig. 2h–j). We also examined the panel of prostate cell lines [69] and confirmed that, on average there is elevated expression of these genes in both prostate cancer cells and transformed prostate cell lines compared to normal prostate cells (Additional file 2: Figure 2A). This suggests a role for BRG1 in maintaining the expression of genes associated with prostate cancer proliferation.

We next sought to further explore commonalities in the genes significantly up- or down-regulated at both time points. We used ‘Enrichr’ [85, 86] to determine which transcription factors had enriched binding at the promoters of these genes in existing ChIP-seq datasets. We discovered that the most significantly enriched datasets were for the AR and FOXA1 (Fig. 3a), both of which are important for prostate cancer growth [66, 67, 87–91].

To investigate the potential coordinated function of these transcription factors with BRG1, we compared the ChIP-seq signal of BRG1 [91], AR [87] and FOXA1 [87] at BRG1 genome-wide binding sites in LNCaP cells in basal cell culture conditions. We found the profiles separated into three clusters. Cluster 1 sites displayed strong AR and FOXA1 binding, cluster 2 had moderate AR and weak FOXA1, and cluster 3 had minimal to no signal for AR or FOXA1 (Fig. 3b). Notably we found binding of all three factors at the promoters of BRG1 regulated genes KLK2 and PCAT1, and binding of BRG1 and FOXA1 upstream of the internal 3-prime promoter of VAV3 (Fig. 3c).

To investigate the cooperative relationship between BRG1, AR and FOXA1 in regulating gene expression, we depleted BRG1 for 144 h and assessed the abundance of AR and FOXA1 recruited to chromatin using cellular fractionation followed by Western blotting. We found that while the majority of AR was unbound, the small fraction of chromatin bound AR was reduced following BRG1 knockdown (Fig. 3d). Additionally, we found that FOXA1 was considerably depleted from the chromatin after BRG1 loss. Our RNA-seq data, as well as total protein levels detected by Western blot, suggest that BRG1 does not significantly alter the overall expression of AR or FOXA1 (Fig. 3d and Additional file 2: Figure 2B-C). Together, suggesting that BRG1 is required for these transcription factors to be loaded onto the chromatin without affecting their overall abundance.

Previous research has shown that BRG1 interacts with AR and FOXA1 in hormone dependent cancers [66, 68, 92, 93]. Therefore, we performed co-immunoprecipitations (co-IP) to see if this interaction was present in our LNCaP model. We found a modest interaction between AR and BRG1 in the AR co-IP, but no interaction between BRG1 and FOXA1, suggesting that in the basal cell culture conditions used in our model these factors do not interact sufficiently to be detected by co-IP (Fig. 3e). However, given the overlap of the ChIP-seq
binding profiles and the fact that BRG1 depletion does not cause concomitant reduction in total AR and FOXA1, we hypothesise that there is either sequential binding of these factors or they are binding in close proximity without directly interacting.

**BRG1 binding is associated with the expression of DNA replication genes**

As the majority of significant gene changes occurred at 144 h post-knockdown, we next investigated the gene regulatory networks that were altered at this time point. Gene ontology analysis with Enrichr [85, 86] identified several significant (FDR < 0.05) GO terms pertaining to some Maintenance (MCM) replicative helicase components in the centre of the binding site. Data are clustered into three groups by k-means. IGV images of the genes KK2, PCAT-1 and I4AV3. Grey shaded regions contain ChIP-seq signal peaks for BRG1, AR and FOXA1. d Representative Western blot of the abundance of soluble unbound proteins versus chromatin bound in control cells and 144 h post BRG1 depletion (n = 3). Vinculin served as the soluble unbound control and H2A as the chromatin bound control. e Representative Western blot of co-IPs for BRG1, AR, FOXA1 and IgG control, alongside the supernatant (unbound fraction) and input representing 1% of the total protein in each sample (n = 3). Samples were collected in basal cell culture conditions in control cells.

(See figure on next page.)

**Fig. 3** BRG1 regulates genes associated with prostate cancer. a Gene set enrichment analysis using ‘Enrichr’ of differentially expressed genes that are common to both time points, showing the adjusted p value (log 10, reversed x-axis) of significantly enriched transcription factor ChIP-seq from ChEA curated data (p < 0.05). b Heatmap of BRG1, AR and FOXA1 ChIP-seq signal at BRG1 binding sites genome-wide in LNCaP cells, ± 2.5 kb from the top 40 most significantly down-regulated genes (Fig. 4a). However, there were no significant common processes related to the up-regulated genes. As BRG1 has previously been shown to interact with cell cycle master regulators, such as Rb and p53 [19, 94–96], we explored the relationship between the cell cycle and BRG1 further in our datasets. We compiled a list of 250 genes related to cell cycle processes, curated from the cell cycle GO terms, and of these examined the top 40 most significantly down-regulated genes in this list from our dataset. Of note among the list were several key genes involved in DNA replication initiation such as CDC6, CDT1 and CDC45, as well as the Minichromosome Maintenance (MCM) replicative helicase components MCM2 and MCM5 (Fig. 4b). To investigate if the effect on replication initiation gene expression was more widespread, we reviewed the gene expression of the other components in the MCM2-7 replicative helicase and the origin recognition complex (ORC) and found that several of these genes were also down-regulated (Fig. 4c, d). We confirmed the down-regulation of MCM5, CDC6 and ORC6 via Western blot, along with cell cycle regulator CHK1, which revealed almost undetectable expression by 144 h post BRG1 knockdown (Fig. 4e, f).

We investigated whether AR and FOXA1 were also co-localised with BRG1 at DNA replication genes. We examined the ChIP-seq binding profiles of AR, FOXA1 and BRG1 at the promoters of 91 DNA replication genes (determined from the DNA replication GO terms) that were expressed in LNCaP cells. We found that promoters of DNA replication genes containing the active histone marks H3K4me3 and H3K27ac also displayed a weak BRG1 ChIP-seq signal, but were completely absent of AR and FOXA1 ChIP-seq signal (Additional file 3: Figure 3A), for example at the promoters of CDC45, ORC6 (Additional file 3: Figure 3B). Additionally, we also note this pattern at a putative enhancer region within the MCM2 gene (Additional file 3: Figure 3B). Our data suggest that BRG1 binding is associated with the expression of DNA replication genes in prostate cancer cells that is independent of AR and FOXA1.

**BRG1 depletion reduces proliferation**

Given BRG1 regulates several genes involved in proliferation and replication; we next asked if BRG1 depletion would alter cell cycle progression in LNCaP cells. We investigated this utilising the same siRNA-mediated approach to target BRG1 by depleting SMARCA4 and conducted flow cytometry cell cycle analysis at 72 and 144 h post-knockdown. We detected an increase of cells in G1 at 72 h, which was enhanced by 144 h. Specifically, at 144 h post BRG1 depletion there was ~20% increase of cells in G1 and equivalent loss of cells in S phase (Fig. 5a, b). To confirm the increase in G1 population was indicative of a reduction in proliferation, we tracked the growth of LNCaP cells stably transformed with H2B-tagged mCherry using live cell imaging. We counted nuclei based on H2B–mCherry fluorescence and found that the controls cells continued to proliferate across the entire time course which we extended to 216 h from the point of siRNA transfection (Fig. 5c). However, the growth of the BRG1 depleted cells began to slow from ~48 h post-knockdown and showed no increase in the number of nuclei from 72 h until the end of the time course (Fig. 5c). Moreover, Western blot of mitosis markers Cyclin A2 and phosphorylation of Serine10 on H3 was significantly reduced at 144 h post BRG1 depletion (Fig. 5d, e). We investigated putative mechanisms underlying reduced proliferation in BRG1 depleted cells. Western blots of senescence regulators p21 and p16 showed no
| Gene       | Experiment          | Organism          |
|------------|---------------------|-------------------|
| AR         | ChIP-Seq LNCaP-1F5  | Human             |
| BACH1      | ChIP-PCR HELA and SCP4 | Human         |
| FOXA1      | ChIP-Seq VCAP       | Human             |
| ZNF217     | ChIP-Seq MCF-7      | Human             |
| FOXM1      | ChIP-Seq MCF-7      | Human             |
| AR         | ChIP-Seq PROSTATE CANCER | Human       |
| FOXA1      | ChIP-Seq LNCaP-1F5  | Human             |
| SOX2       | ChIP-Seq SW620      | Human             |
| HNF4A      | ChIP-Seq HepG2      | Human             |
| ESR1       | ChIP-ChIP LIVER     | Mouse             |

**Figure a**

| Gene       | Adj. p-value (log 10) |
|------------|-----------------------|
| AR         | 10^{-5}               |
| 10^{-4}    |
| 10^{-3}    |
| 10^{-2}    |
| 10^{-1}    |
| 10^{0}     |
| 10^{1}     |
| 10^{2}     |
| 10^{3}     |

**Figure b**

| Gene       | Distance from center of BRG1 binding site +/- 2.5kb |
|------------|-----------------------------------------------------|
| BRG1       | 0.100 - 0.50                                       |
| AR         | 0 - 25                                             |
| FOXA1      | 0 - 25                                             |
| H3K4me3    | 0 - 2.00                                           |
| H3K27ac    | 0 - 10.00                                          |
| H3K4me1    | 0 - 5.00                                           |
| H3K27me3   | 0 - 1.00                                           |

**Figure c**

| Gene       | Chromatin Bound |
|------------|-----------------|
| BRG1       | Total Protein   |
| AR         | Unbound         |
| FOXA1      | Chromatin Bound |

**Figure d**

| Gene       | IP Unbound     |
|------------|----------------|
| BRG1       | Input          |
| AR         | BRG1           |
| FOXA1      | FOXA1          |
| Vinculin   | BRG1           |

**Figure e**
increase at 144 h post BRG1 knockdown, indicating that senescence was not activated (Fig. 5f). We also monitored the activity of caspase 3 in live fluorescence imaging as an apoptosis readout. LNCAp cells were monitored for 24 h before treatment with a combination of 50 µg/ml of tumour necrosis factor-α (TNFα) and 100 nM of SM164 to induce apoptosis, or 2 µM of the DNA polymerase inhibitor aphidicolin to induce S-phase arrest. As expected, TNFα and SM164 induced apoptosis within 24 h (Additional file 4: Figure 4A). Apoptosis was also observed in untreated or control siRNA transfected cells starting at four days in culture (Fig. 5g, Additional file 4: Figure 4A). However, aphidicolin treatment or BRG1 depletion suppressed the delayed apoptosis (Fig. 5g, Additional file 4: Figure 4A). Our RNA-seq data demonstrate that BRG1 depleted cells maintain caspase 3, caspase 8 and caspase 9 expression (Additional file 4: Figure 4B), indicative of an intact apoptosis pathway. The
most likely interpretation of these data is that culture crowding in untreated or control siRNA cells becomes lethal, and that slowing proliferation with BRG1 depletion or aphidicolin rescues apoptosis induction. Therefore, neither apoptosis nor senescence was responsible for reduced proliferation in BRG1 depleted cells. We anticipate the observed reduction in proliferation stems from a failure to initiate replication, consistent with down-regulated CDC6, ORC5 and MCM proteins.

**Discussion**

Here, we examined the involvement of the SWI/SNF chromatin remodeler BRG1 and its associated encoding gene SMARCA4 in prostate cancer transcriptional deregulation. We found that over expression of SMARCA4 commonly occurs in both the TCGA prostate cancer cohort, irrespective of tumour subtype, and in a panel of prostate cancer cell lines. We also found that knockdown of the SMARCA4 gene, and consequently the BRG1 protein, results in down-regulation of pro-proliferative transcriptional pathways. These included genes already known to promote prostate cancer proliferation, as well as cell cycle and DNA replication genes. Reduction of gene expression in these pathways was concomitant with G1 arrest. Taken together, our results provide new insights into BRG1’s contribution to transcriptional patterns relating to proliferation in prostate cancer.

We have demonstrated that SMARCA4 mRNA over expression is a universal feature of prostate cancer. Clinical datasets have shown that BRG1 protein levels are over-expressed in prostate cancer, in the absence of consistent significant deleterious genetic mutations evident in SMARCA4 [42, 44–46]. Using the large prostate cancer cohort from TCGA [50], we found that SMARCA4 was significantly over-expressed. Consistent with this, SMARCA4 expression was increased in a panel of both prostate cancer and transformed cell lines. These data emphasise that the overall increased expression of SMARCA4 is a characteristic of prostate cancer, irrespective of subtype.

BRG1 depletion followed by RNA-seq revealed multiple transcriptomic alterations that were regulated by BRG1 and related to proliferation. BRG1 depletion primarily resulted in the down-regulation of BRG1’s target genes, indicating that the main role of BRG1 is to promote active gene expression. Within the down-regulated genes were genes associated with increased proliferation in prostate cancer including KLK2, PCAT-1 and VAV3. KLK2 is a known activator of PSA, which is an important biomarker of prostate cancer, and associated with decreased apoptosis [77, 84]. PCAT-1 promotes proliferation through the oncoprotein Myc [69, 81], while VAV3 regulates AR activity to stimulate growth in prostate cancer [78–80, 82]. Both PCAT-1 and VAV3 are correlated with disease progression. Through an analysis of gene ontologies, we also found several cell cycle gene pathways were down-regulated with BRG1 depletion. This included numerous genes involved in DNA replication, which were among the most significantly down-regulated genes following BRG1 depletion. BRG1 is known to have a role in driving self-renewal and malignancy in B-cell acute lymphoblastic and acute myeloid leukaemias, cancers which also have over expressed BRG1 [22, 24]. Specifically, these leukaemias require high levels of BRG1 for de-condensation of the cell-specific MYC enhancer. In these cancers, a loss of BRG1 causes a reduction of enhancer–promoter interactions, reduced transcription factor occupancy and DNA looping which in turn reduces MYC expression [24]. This implies that the over-expression of BRG1 contributes to driving oncogenic transcriptional programmes which influence the proliferation capacity of cancer cells.

Our data revealed that BRG1 co-regulates the promoters of proliferation associated genes (KLK2, PCAT-1 and VAV3) along with AR and FOXA1, and that these genes become down-regulated across our experimental time course of BRG1 depletion. Co-regulation of transcription by AR and FOXA1 in prostate cancer is associated with reprogrammed binding of AR and oncogenic patterns of gene expression that are essential for AR-driven
proliferation [92, 97]. Additionally, there is a high overlap of these reprogrammed AR binding sites between LNCaP cells and primary prostate tumour tissue [97]. Here, we have shown BRG1 gene regulation overlaps with these transcription factors at gene promoters, which is concomitant with expression of prostate cancer associated genes. We also demonstrated that depletion of BRG1 affects the level of chromatin binding for both AR
and FOXA1. However, we did not find significant direct interaction by co-IP. This differs from direct interactions between these proteins observed others in previous works [66, 68, 92, 93] likely due to different experimental approaches. For example, we have investigated BRG1 interactions in basal cell culture conditions, while for example, Stelloo et al. [92] looked at AR interactions in the presence of synthetic androgens.

It is noteworthy that BRG1 depletion altered the expression of DNA replication genes through a mechanism that appears independent of AR and FOXA1, suggesting that BRG1 has additional roles in other gene regulatory networks. As BRG1 is known to regulate cell cycle genes in other cancers, such as in leukaemia [24] and breast cancer [98], we speculate it is possible that regulation of cell cycle and DNA replication genes may be a general feature of BRG1 over expression in cancer, while genes co-regulated by BRG1, AR and FOXA1 are important in a prostate cancer context.

Conclusions
In summary, our data identify fundamental role for BRG1 in maintaining active transcription for proliferation of prostate cancer cells. We find that BRG1 promotes gene expression in prostate cancer models with varying degrees of dependence on AR and FOXA1. BRG1 is required to drive the expression of numerous prostate cancer specific genes in an AR/FOXA1 dependent manner, but also works independently to drive the expression of pro-proliferative and DNA replication genes. These results provide important functional information regarding the role of BRG1 controlling proliferation in prostate cancer cells.

Materials and methods
Cell culture and siRNA transfection
Normal prostate epithelial cells (PrEC) (Cambrex Bio Science, CC-2555) were cultured in PrEBM (Clonetics, CC-3165) according to the manufacturer’s protocol. Briefly, PrEC cells were seeded at 2500 cells per cm² and medium was replaced every two days. Cells were passaged at approximately 80% confluence. To passage a T75 flask, PrEC cells were rinsed in 6 ml Hanks balanced salt solution (Thermo Fisher Scientific, 14025076) then detached with 2 ml pre-warmed 0.025% trypsin–EDTA and incubated at room temperature for 5 min. Trypsin was inactivated with 12 ml of trypsin-neutralising solution (Clonetics, CC-5002), and cells were centrifuged at 300 × g for 5 min. The supernatant was aspirated, and the cell pellet was re-suspended in PrEBM. The number of cells was determined on the Countess automated counter and was re-seeded at the appropriate density based on experimental needs. Cells were discarded after ~ 16 population doublings.

PC3 cells (ATCC, CRL-1435) were maintained in RPMI medium (Gibco, 11875-093) with 10% FBS, 11 ml of 1 M HEPES (Gibco, 15630080) and Pen/Strep. LNCaP cells (ATCC, CRL-1740) were cultured using custom T-Medium from Gibco (DMEM low glucose (GIBCO, 31600-034), Kaighn's modified F-12 medium (F-12 K, 211227-014), insulin 500 × bovine pancreas (Sigma I1882), T3 6.825 ng/ml Tri-iodothyronine (Sigma-Aldrich, T5516), Transferrin 500× (Sigma-Aldrich, T5391), Biotin 500× (Sigma-Aldrich, B4639), Adenine 500× (Sigma-Aldrich, A3259)). Both prostate cell lines were cultured under recommend conditions; 37 °C with 5% CO₂. When the cells reached ~ 80% confluence they were passaged or seeded as per experimental requirements. For siRNA transfection, LNCaP cells were seeded into 6-well plates at a density of 2.5 × 10⁵ cells per well or 10 cm dishes at 1.5 × 10⁶ cells per dish. The cells were transfected with either on target SMARCA4 siRNA (Horizon, J-010431-06-0005 [si-SMARCA4-1] or J-010431-07-0005 [si-SMARCA4-2]) or the non-targeting control siRNA pool (Horizon, D-001810-10-05 [si-NT]) 24 h after seeding the cells using DharmaFECT 2 (Thermo Scientific, T-2002-03) as per the manufacturer's instructions. To maintain the knockdown over a 6-day period, at 72 h post-transfection the cells were harvested, split at a ratio of 1:2 into two new wells and reverse-transfected with siRNA. The cells were then incubated for a further 72 h before collection.

Viral transduction and selection of H2B–mCherry LNCaP cells
Replication incompetent lentiviral particles were produced by transfecting the pLXSN-H2B–mCherry plasmid (kindly provided by A. J. Cesare) into Phoenix cells and collecting the supernatant after 48 h. LNCaP cells were seeded into 6-well plates in antibiotic free media at 2 × 10⁵ cells per well. After 24 hrs, 2 mL of viral supernatant, mixed with fresh media at 1:1 ratio, was added to the cells. This was replaced with fresh media after 24 h and the cells were allowed to recover for a further 24 h before checking for the presence of mCherry fluorescence. mCherry positive cells were selected for with 600 μg/ml of G418 (Sigma-Aldrich, A1720). Cells were monitored for cell death and media replaced and cells passaged as necessary. After 7 days, G418 was reduced to 50%; the cells were maintained in G418 for live cell imaging experiments.
**Growth assay**

siRNA knockdown was performed as described for LNCaP cells containing the stable expression of mCherry–H2B fusion protein. At the point of siRNA transfection, the cells were placed in the Incucyte live cell imaging system (Sartorius). Images were taken every 2 h for 216 h with 16 images captured per well of a 6-well plate. The mean score each of the 16 photos per well was reported as the number or nuclei per mm². Relative fold change was calculated by the difference between 0 h and each two-hour window up to 72 h and then after re-seeding the cells between 72 h and each two-hour window until the end of the time course. A significant change was calculated by one-way ANOVA and corrected with Tukey’s test for multiple comparisons. Sample reducing agent (Thermo Scientific, NP0004), loading buffer (Thermo Scientific, NP0007) and 10 μg protein were combined with water to a final volume of 25 μl. Protein samples were heated at 90 °C for 5 min then allowed to cool to room temperature. Protein samples were loaded on a NuPage Novex Bis–Tris 4–12% gel (Thermo Scientific, NP0321BOX) and electrophoresed at 100 V for 1.5 h in a 1 x MOPS buffer (50 mM MOPS (Biochemicals Astral Scientific), BIOMB03600, 50 mM Tris base, 0.1% SDS, 1 mM EDTA [pH 7.7]). Proteins were transferred to a polyvinylidene fluoride membrane (Bio-Rad, 1620177) at 30 V for 1 h using 1 x transfer buffer (25 mM Tris base, 192 mM Glycine [pH 8.3]) with 10% methanol (Sigma-Aldrich, 322415). Membranes were blocked for 1 h with 5% skim milk in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20 [pH 7.6]) at 4 °C. Primary antibodies used were BRG1 (Santa Cruz, sc-10768X), GAPDH (Ambion, AM4300), CHK1 (CST, 2360S), ORC6 (CST, 4737S), CDC6 (CST, 3387S), MCM5 (abcam, ab17967), AR (CST, D6F11), FOXA1 (CST, E7E8W), Vinculin (Sigma-Aldrich, V9131), H2A (CST, 12349S), p21 (CST, 2349S), p16 (CST, 92803S), Cyclin A2 (Abcam, ab181591) and pH3(Ser10) (CAT, 3377S). Primary antibodies were incubated on samples overnight at 4 °C with rotation. The membrane was then washed three times for 10mins each in TBS-T with rotation. Secondary antibodies goat anti-mouse (Santa Cruz, sc-2005) and goat anti-rabbit (Santa

**Caspase-3 apoptosis assay**

LNCaP cells were seeded in a 96-well plate at 4000 cells per well, with up to 8 technical replicates per condition. After 24hrs, all cells were treated with NucView Caspase-3 Enzyme Substrate 488 (Biotium, 10402), and appropriate wells also treated with siRNA as described above, then placed in the Incucyte live cell imaging system (Sartorius). One image per well was taken every 2 h for 7 days. After 24 h in the Incucyte, the positive control cells were treated with either 50 μg/ml of TNFα (Sigma-Aldrich, H8916) + 100 nM of SM164 (Selleckchem, S7089), or 2 μM of Aphidicolin (Sigma-Aldrich, A0781). Integrated fluorescence intensity was calculated within the Incucyte Zoom software using the summed pixel intensity in calibrated units (CU) to determine the relative fluorescence units per image with the following equation; CU x μm²/image. A significant change was calculated by one-way ANOVA, with each BRG1 on-target siRNA compared to the non-targeting control. The results were corrected for multiple comparisons with Dunnett’s test. A significant change is defined as ****p<0.0001.

**Quantitative real-time PCR (qRT-PCR)**

RNA was extracted with TRIzol reagent (Thermo Scientific, 15596026), according to the manufacturer’s protocol. Extracted RNA was re-suspended in 30 μl of nuclelease-free water and quantified on the NanoDrop spectrophotometer (Thermo Scientific). cDNA synthesis was carried out with 500 ng of RNA using the SensiFAST cDNA Synthesis Kit (Bioline, BIO-65054) according to the manufacturer’s instructions.

qRT-PCR was carried out on the CFX384 Touch Real-Time PCR Detection System (Bio-Rad). A master mix was made for each qRT-PCR target containing 5 μl of KAPA Universal SYBR Fast PCR mix (KAPA Biosystems, KK4602), 0.6 μl of 5 μM forward primer, 0.6 μl of 5 μM reverse primer and 1.8 μl of nuclelease-free water per reaction. Reactions conditions were 95 °C for 3 min, followed by 45 x cycles of 95 °C for 3 s and 60 °C for 30 s, then a melt curve analysis (65–95 °C, increasing at a rate of 0.5 °C every 5 s). Primers to detect SMARCA4 were CAGAACGCACAGCCTTCAA (forward) and TCA CTCTCTCGGCTTCACT (reverse) and for detection of 18S GGGACCTTAATCAAACGCAAGC (forward) and GCAATTATCCCCATGAACG (reverse). Relative gene expression was calculated using ddCt and normalised to 18S. A significant change in gene expression of SMARCA4 between PrEC, LNCaP and PC3 cells was determined by one-way ANOVA and corrected with Tukey’s test for multiple comparisons.

**Western blot**

Whole-cell lysates were collected with lysis buffer (50 mM HEPES, 150 mM NaCl, 10% Glycerol, 1% Triton-X-100, 1.5 mM MgCl₂, 1 mM EGTA, 10 mM Pyrophosphate, 100 mM NaF, Roche protease inhibitor cocktail 1 x), and protein level quantified using the Pierce BCA Assay Kit (Thermo Scientific, 23227) according to the manufacturer’s instructions. Sample reducing agent (Thermo Scientific, NP0004), loading buffer (Thermo Scientific, NP0007) and 10 μg protein were combined with water to a final volume of 25 μl. Protein samples were heated at 90 °C for 5 min then allowed to cool to room temperature. Protein samples were loaded on a NuPage Novex Bis–Tris 4–12% gel (Thermo Scientific, NP0321BOX) and electrophoresed at 100 V for 1.5 h in a 1 x MOPS buffer (50 mM MOPS (Biochemicals Astral Scientific), BIOMB03600, 50 mM Tris base, 0.1% SDS, 1 mM EDTA [pH 7.7]). Proteins were transferred to a polyvinylidene fluoride membrane (Bio-Rad, 1620177) at 30 V for 1 h using 1 x transfer buffer (25 mM Tris base, 192 mM Glycine [pH 8.3]) with 10% methanol (Sigma-Aldrich, 322415). Membranes were blocked for 1 h with 5% skim milk in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20 [pH 7.6]) at 4 °C. Primary antibodies used were BRG1 (Santa Cruz, sc-10768X), GAPDH (Ambion, AM4300), CHK1 (CST, 2360S), ORC6 (CST, 4737S), CDC6 (CST, 3387S), MCM5 (abcam, ab17967), AR (CST, D6F11), FOXA1 (CST, E7E8W), Vinculin (Sigma-Aldrich, V9131), H2A (CST, 12349S), p21 (CST, 2349S), p16 (CST, 92803S), Cyclin A2 (Abcam, ab181591) and pH3(Ser10) (CAT, 3377S). Primary antibodies were incubated on samples overnight at 4 °C with rotation. The membrane was then washed three times for 10mins each in TBS-T with rotation. Secondary antibodies goat anti-mouse (Santa Cruz, sc-2005) and goat anti-rabbit (Santa
were then eluted in 40 μl of 2 × LDS buffer and frozen at −20 °C. Detection of proteins that immunoprecipitated with the target was performed by Western blot, which was run with the input which represents 1% of the total protein in the co-IP.

**Flow cytometric cell cycle analysis**

LNCaP cells were seeded at 1.5 × 10⁶ cells per 10 cm dish and transfected with siRNA as described. At 72 and 144 h post-transfection, the cells were treated with 10 μM EdU (Sigma-Aldrich, 900584) for 30 min. Remaining EdU was washed off the cells with PBS before harvesting cells, and then, 1 × 10⁶ cells were fixed in 70% ethanol and frozen at −20 °C. Cells were then diluted 1 in 4 with PBS then pelleted and re-suspended in 1 ml of PBS containing 1% BSA (Sigma-Aldrich, A2058). Cells were again pelleted, re-suspended in 500 μl of click reaction mix (10 μM carboxyfluorescein TEG-azide, 10 mM Sodium L-ascorbate and 2 mM Copper-II-sulphate diluted in PBS), and incubated in the dark at room temperature for 30 min. Samples were then diluted with 5 ml of PBS containing 1% BSA and 0.1% Tween-20. Cells were again pelleted, washed with PBS and then re-suspended in 500 μl of PBS containing 1% BSA, 0.1 mg/ml of RNase and 1 μg/ml of DAPI. Samples were analysed on the Canto II (BD Biosciences). Forward and side scatter were used to select a population of cells free of cell debris and doublets. Cells were analysed using B450 (FTIC – EdU positive) and B510 (DAPI) lasers. 50,000 single-cell events were recorded for each sample. FlowJo software v10.5 was used to analyse the data. Data were collected in biological triplicate.

**RNA-seq experiments**

Total RNA was extracted with TRIzol reagent (Thermo Fisher, 15596026), quantified on the Qubit and quality assessed with the Bioanalyzer. An aliquot of 500 ng of total RNA was spiked with external controls ERCC RNA spike-in Mix (Thermo Scientific, 4456740) and libraries constructed with the TruSeq Stranded mRNA sample preparation kit (Illumina, 20020594) according to the manufacturer’s protocol. mRNA Libraries were quantified on Qubit and then stored at −20 °C. Library quality and fragment size of RNA-seq libraries were assessed on the Bioanalyzer, and then, KAPA Library Quantification (KAPA Biosystems, KK4824) was performed according to the manufacturer’s protocol. The KAPA quantification results were used to dilute the libraries to 2 nM for sequencing. RNA-seq samples were sequenced for 100 cycles of paired-end reads on the Illumina HiSeq 2500 platform, with four samples multiplexed per lane of the high output run.
RNA-seq data analysis
RNA-seq data were processed as described in Taberlay & Achinger-Kawecka et al. [9]. Briefly, read counts were normalised with ERCC spike in controls, mapped to hg19/GRCh37 using STAR and counted into genes using the featureCounts [101] programme. GENCODE v19 was used as a reference transcriptome to determine the transcript per million read (TPM) value. Fold change was calculated within each time point as the log2 ratio of normalised reads per gene using the edgeR package in R. Genes with a fold change of ±1.5 and FDR < 0.01 were considered significantly different. Volcano plots of differential expression were created in R with ggplots2 and heatmaps with the heatmap2 package with normalised row Z-score. PCA was performed in R using the edgeR package with log counts per million (logCPMS) over GENCODE v19 annotated gene coordinates and normalising the read counts to library size. RNA-seq multi-variate analysis of transcript splicing (MATS) to calculate exon skipping and intron retention was performed with the MATS python package v4.0.2 [73–75]. Transcription factor and GO term enrichment was obtained from Enrichr (http://amp.pharm.mssm.edu/Enrichr/) online gene list analysis tool [85, 86].

TCGA and prostate cell line expression analysis
Pre-processed RNA-seq data from the TCGA prostate adenocarcinoma cohort were downloaded (cancergenome.nih.gov) for both normal and tumour samples. The average of tumour (n = 486) and normal (n = 52) samples was calculated to determine mean expression. Separation of tumours by Gleason score and molecular subtype was performed in R using the associated clinical data to subset the appropriate groups. Significance was calculated for tumour versus normal using an unpaired t test. For comparison between Gleason score or molecular subtype, significance was calculated using one-way ANOVA with Dunnett’s multiple comparison correction.

Expression data for prostate cell lines from Presner et al. [69] were downloaded from http://www.betastasis.com/prostate_cancer/. Significance between normal, cancer, and transformed cell lines was calculated using one-way ANOVA with Dunnett’s multiple comparison correction.

ChIP-seq data
The following LNCaP ChIP-seq data were obtained from GEO (ncbi.nlm.nih.gov/geo/); BRG1 accession GSE72690 [91], H3K4me3 and H3K27me3 accession GSE38685 [102], H3K27ac and H3K4me1 accession GSE73785 [9]. These data were processed through NGSsane pipeline as previously described [9, 102]. Pre-processed bigwig files for FOXA1 and AR were obtained from GEO accession GSE114274 [87]. Genome browser images of ChIP-seq data were taken from IGV. Heatmaps of ChIP-seq signal were created with deepTools [103].

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01023-7.

Additional file 1. Figure 1 a SWI/SNF subunit gene expression (TPM) from RNA-seq data. All subunits, except SMARCA4 (shown in Fig. 2a), are not significantly altered. Bars denote mean, and error bars are SD. b PCA plot characterising the trend in expression profiles between the non-targeting control and after BRG1 knockdown. Each point on the plot represents an RNA-seq sample. Samples are separated by principal components 1 and 2, which together explain 58.37 % of the variance between the samples. c Number of skipped exons at 72 hours and 144 hours after BRG1 knockdown with si-SMARCA4-1 (black) and si-SMARCA4-2 (grey). d Number of retained introns at 72 hours and 144 hours post BRG1 depletion with si-SMARCA4-1 (black) and si-SMARCA4-2 (grey). e Sashimi plot of exons one and two of the KLK3 gene in the non-targeting and 144 hour knockdown RNA-seq data. Arcs represent the number of split reads across the exons. Lower numbers represent increased retention of the first intron after BRG1 knockdown.

Additional file 2. Figure 2 a Expression of KLK2, PCAT-1 and VAV3 in prostate cell lines grouped as normal, cancer or transformed. b AR and FOXA1 gene expression from the RNA-seq datasets shown as TPM. Bars denote mean, and error bars are SD.

Additional file 3. Figure 3 a Heatmap of replication gene promoters, +/- 5kb from the transcription start site. b IGV images of the genes CDC45, ORC6 and MCM2. Grey shaded regions contain ChIP-seq signal peaks for BRG1 and active histone modifications.

Additional file 4. Figure 4 a Relative fluorescence units of caspase-3 activity determined from live-cell imaging over the course of 7 days. Treatments were added 24 hours after initial imaging. b CASP3, CASP8 and CASP9 gene expression from the RNA-seq datasets shown as TPM. Bars denote mean, and error bars are SD.

Abbreviations
AR: Androgen receptor; BRG1: Brahma-related gene 1; FOXA1: Forkhead box A1; KLK2: Kallikrein 2; MCM: Minichromosome maintenance; ORC: Origin recognition complex; PCAT1: Prostate cancer associated transcript 1; PreC: Prostate epithelial cells; PSA: Prostate specific antigen; MATS: Multivariate analysis of transcript splicing; Rb: Retinoblastoma protein; SMARCA4: SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4; SWI/SNF: Switch/sucrose non-fermentable; TCGA: The cancer genome atlas; VAV3: Vav guanine nucleotide exchange factor 3.

Acknowledgements
We thank Suat Dervish and the Westmead Flow Cytometry facility for the FACS analysis infrastructure.

Authors’ contributions
This study was initiated and designed by KAG, SJC and PCT. Experiments were performed by KAG, SGP, GRK and SR. Analysis and interpretation of next-generation data was performed by KAG, CMG, JAK and PL. Initial manuscript draft was written by KAG. Manuscript editing and reviewing was conducted by KAG, JAK, SGP, GRK, AJC, SJC and PCT. All authors have read and approval the final version of this manuscript. Funding for this work was provided by AJC, SJC and PCT. All authors read and approved the final manuscript.

Funding
This work is supported by grants awarded to AJC, SJC and PCT. AJC is supported by grants from the NHMRC (1162886, 1189870), the Goodfriidge Foundation and the Neil and Norma Hill Foundation. SJC is supported by grants.
(1011447, 1070418, 1051757) and a fellowship (1156408) from the NHMRC. PCT. is supported by grants from the Cure Cancer Australia Foundation (1060713) and the NHMRC (1051757, 1161985), and a fellowship (1109696) and investigator grant from the NHMRC (1176417).

Availability of data and materials
The BRG1 knockdown RNA-seq data generated for this study is available from GEO, accession number GSE150252.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Epigenetics Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. 2 Genome Integrity Unit, Children’s Medical Research Institute, University of Sydney, Westmead, NSW 2145, Australia. 3 Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, TAS, Hobart 7000, Australia. 4 St-Vincent’s School, UNSW Sydney, Sydney, NSW 2000, Australia.

Received: 24 August 2020 Accepted: 4 February 2021

References
1. Giles KA, Taberlay PC. The role of nucleosomes in epigenetic gene regulation. In: Hessom LB, Pritchard AL, editors. Clinical epigenetics. Singapore: Springer; 2019. p. 87–117.
2. Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 2014;24(9):1421–32.
3. Thurman RE, Neri SE, Vierstra J, Maurano MT, Haugen E, et al. The accessible chromatin landscape of the human genome. Nature. 2012;489(7414):75–82.
4. Heintzman ND, Stuart RK, Hon G, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–8.
5. Skulte KA, Phan L, Clark SJ, Taberlay PC. Chromatin remodeler mutations in human cancers: epigenetic implications. Epigenomics. 2013;5(9):585–96.
6. Li XY, Thomas S, Sabo PJ, Eisen MB, Stamatoyannopoulos JA, Biggin MD. The role of chromatin accessibility in directing the widespread, overlapping patterns of Drosophila transcription factor binding. Genome Biol. 2011;12(4):R34.
7. Venkatesh S, Workman JL. Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol. 2015;16(3):178–89.
8. Makova KD, Hardison RC. The effects of chromatin organization on variation in mutation rates in the genome. Nat Rev Genet. 2015;16(4):213–23.
9. Taberlay PC, Achninger-Kawecka J, Lun AT, Buske FA, Sabir K, Gould CM, et al. Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. Genome Res. 2016;26(6):719–31.
10. Hu Z, Chen K, Xia Z, Chavez M, O’Connell S, Seol JH, et al. Nucleosome loss leads to global transcriptional up-regulation and genomic instability during yeast aging. Genes Dev. 2014;28(4):396–408.
11. O’Sullivan RJ, Kubicek S, Schreiber SL, Karasaki J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol. 2010;17(10):1218–25.
12. Giles KA, Taberlay PC. Mutations in chromatin remodeling factors. In: Pfeifer G, editor. Encyclopedia of cancer. 3rd ed. United States: Elsevier; 2019. p. 511–27.
13. Reisman D, Garo S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28(14):1653–68.
14. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE. 2013;8(1):e55119.
15. Wilson BG, Roberts CW. SWI/SNF nucleosome remodelers and cancer. Nat Rev Cancer. 2011;11(7):481–92.
16. Chu X, Guo X, Jiang Y, Wu H, Liu L, Shan W, et al. Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers - initial evidence of an oncogenic role for CHD7. Mol Oncol. 2017;11(10):1348–60.
17. Kadow C, Hargreaves DC, Hodgson C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592–601.
18. Dunafie JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell. 1994;79(1):119–30.
19. Strober BE, Dunafie JL, Guha GSP. Functional interactions between the hBRC1/hBRG1 transcriptional activators and the pRb family of proteins. Mol Cell Biol. 1996;16(4):1576–83.
20. Yokoyama Y, Matsushita Y, Shigeto T, Futagami M, Mizunuma H. Decreased ARID1A expression is correlated with chromoerosis in epithelial ovarian cancer. J Gynecol Oncol. 2014;25(1):58–63.
21. Li M, Song C, Walter V, Karaca M, Li Y, Bartlett CS, Smiraglia DJ, et al. Gene silencing associated with SWI/SNF complex loss during NSCLC development. Mol Cancer Res. 2014;12(4):560–70.
22. Buscarlet M, Krasteva V, Ho L, Simon C, Hebert J, Wilhelm B, et al. Essential role of BRG1, the ATPhase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood. 2014;11(1):720–8.
23. Yang HB, Wang XF, Zhang Q, Tang ZQ, Jiang YH, Fan HZ, et al. Reduced expression of the chromatin remodelling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis. 2013;35:867–76.
24. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013;27(24):2468–62.
25. Romero OA, Torres-Diz M, Pros E, Sàvola S, Gomez A, Moran S, et al. MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2013;3:292–303.
26. Oike T, Ogawara H, Nakano T, Yokota J, Kohno T. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer. Jpn J Clin Oncol. 2013;43(9):849–55.
27. Mao TL, Ardigheri L, Ayhan A, Kuo KT, Wu CH, Wang TL, et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 2013;37(9):1342–8.
28. Cho H, Kim JS, Chung H, Perry C, Lee C, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013;44(7):1365–74.
29. Bosse T, ter Haar NT, Seeker LM, van Dijk PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013;26(11):1525–35.
30. Bai J, Mei P, Zhang C, Chen F, Li C, Pan Z, et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS ONE. 2013;8(3):e59772.
31. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;21(1):19–20.
32. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, et al. Loss of ARID1A expression is related to shorter progression-free survival and chromoerosis in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282–90.
33. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 2009;8(5):412–6.
34. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Nat Rev Cancer. 2012;12(6):391–401.
35. Wen X, Khan SA, Shih J, Wang FF, Liu L, Tang X, et al. Loss of ARID1A expression is related to shorter progression-free survival and chromoerosis in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282–90.
36. Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendrics K, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 2000;60(21):6171–7.
37. Medina PP, Romero OA, Kohen T, Montuenga LM, Pio R, Yokota J, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat. 2008;29(5):617–22.
38. Roberts CW, Orkin SH. The SWI/SNF complex–chromatin and cancer. Nat Rev Cancer. 2004;4(2):133–42.
39. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014;34(6):1136–44.
40. Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, et al. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol. 2017;26:47–51.
41. Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A, Haller F. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 (neg)/CK7 (pos)/HepPar-1 (pos) immunophenotype. Virchows Arch. 2017;471(5):590–600.
42. Sun A, Tawﬁk O, Gayed B, Thrasher JB, Hoestje S, Li C, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007;67(2):203–13.
43. Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q, et al. Chromatin remodeling ATPase subunit BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019;129(2):759–73.
44. Liu XB, Sun AJ, Wang C, Chen LR. Expression of BRG1 and BRM proteins in prostatic cancer. Zhonghua Bing Li Xue Za Zhi. 2010;39(9):591–4.
45. Li Y, Shi QI, Jin XZ, Meng K, Zhou XJ, Sun LP. BRG1 expression in prostate carcinoma by application of tissue microarray. Zhonghua Nan Ke Xue. 2006;12(7):629–32.
46. Valdman A, Nordenskjold A, Fang X, Naito A, Al-Shukri S, Larsson C, et al. The chromatin remodeler BRG1 activates enhancer repertoires to establish B cell identity and modulate cell growth. Nat Immunol. 2015;16(7):775–84.
47. Ni Z, Abou El Hassan M, Xu Z, Yu T, Bremner R. The chromatin-remodeling enzyme BRG1 coordinates CITA induction through many interdependent distal enhancers. Nat Immunol. 2008;9(7):785–93.
48. Nam M, Lee J, Lajoie BR, Fagerberg L, Zhou Q, Li Y, et al. SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells. Genome Res. 2016;26(9):1188–201.
49. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Cancerogenesis. 2008;29(9):1725–33.
50. Marshall TW, Link KA, Petre-Draviam CE, Knudsen KE. Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem. 2003;278(33):30605–10.
51. Hoffmann JA, Trotter KW, Ward JM, Archer TK. BRG1 governs glucocorticoid receptor interactions with chromatin and pioneer factors across the genome. Elife. 2018;7:e35073.
52. Oikawa H, Togawa K, Inoue K, Oda A, Tsuta K, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 2013;73(17):5508–18.
53. Murthuuswami R, Bailey L, Rakshes R, Imbalzano AN, Nickerson JA, Hockenmous JW. BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. J Clin Physiol. 2019;234(9):15194–205.
54. Genome Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.
55. Tostorukov MF, Sansam CG, Lu P, Koelleffor EC, Helming KC, Alver BH, et al. SWI/SNF chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 2013;110(25):10165–70.
56. Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI/SNF chromatin remodeling complex is required for maintenance of lineage specific enhancers. Nat Commun. 2017;8:14084.
57. Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, et al. Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. Nat Struct Mol Biol. 2018;25(1):61–72.
58. Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, et al. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res. 2011;21(10):1650–8.
59. Bao X, Rubin AJ, Qu K, Zhang J, Giresi PG, Chang HY, et al. A novel ATAC-seq approach reveals lineage-specific reprogramming of the open chromatin landscape via cooperation between BAF and p63. Genome Biol. 2015;16:284.
60. Giles KA, Gould CM, Du Q, Skvortsova K, Song JZ, Maddugoda MP, et al. Integrated epigenomic analysis stratifies chromatin remodelers into distinct functional groups. Epigenetics Chromatin. 2019;12(1):12.
61. Luebben WR, Sharma N, Nyborg JK. Nucleosome eviction and activated transcription require p300 acetylation of histone H3 lysine 14. Proc Natl Acad Sci USA. 2010;107(45):19254–9.
79. Liu Y, Mo JQ, Hu Q, Boivin G, Levin L, Lu S, et al. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res. 2008;68(15):6396–6406.

80. Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 2006;20(5):1061–72.

81. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014;16(11):900–8.

82. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, et al. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 2012;31(6):716–27.

83. Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, et al. LncRNA PCAT-1 promotes prostate cancer cell proliferation and invasion by activating AKT and NF-kappaB signaling. Mol Endocrinol. 2006;20(5):1061–72.

84. Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostatitis and prostate cancer. Cancer Res. 2008;68(15):6396–406.

85. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: an interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14:128.

86. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nuc Acids Res. 2016;44(W1):W90–7.

87. Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci USA. 2011;108(29):14573–82.

88. Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, et al. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget. 2015;6(30):29782–94.

89. Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA, et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol. 2011;31(23):4648–62.

90. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 2015;34(4):302–16.

91. Ye Z, Chen Z, Sunkel B, Friezle S, Huang TH, Wang Q, et al. Genome-wide analysis reveals positional-nucleosome-oriented binding pattern of pioneer factor FOXA1. Nucl Acids Res. 2016;44(16):7540–54.

92. Stelloo S, Nevedomskaya E, Kim Y, Hoekman L, Bleijerveld OB, Mirza T, et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene. 2018;37(3):313–22.

93. Nacht AS, Pohl A, Zaurin R, Soronellas D, Queloz J, Sharma P, et al. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 2006;20(5):1061–72.

94. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014;16(11):900–8.

95. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, et al. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 2012;31(6):716–27.

96. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nuc Acids Res. 2016;44(W1):W90–7.

97. Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci USA. 2011;108(29):14573–82.

98. Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, et al. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget. 2015;6(30):29782–94.

99. Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA, et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol. 2011;31(23):4648–62.

100. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 2015;34(4):302–16.